Paterson Dan

Avg. Two Year Performance

(82%) Avg. Purchase Return
(35%) Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return(12%)(19%)(36%)(71%)(82%)
Purchase Success Rate1 of 42 of 41 of 41 of 40 of 4
Average Sale Return0%0%0%0%0%
Sale Success Rate0 of 10 of 10 of 10 of 10 of 1

Verastem, Inc.

Drugs » Biotechnology

President and CEO, Director:

Holdings: 232.39K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--